Research To Practice | Oncology Videos

Latest Episodes:

Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances Jun 10, 2025

Show notes

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics:

Introduction: Actionable Genomic Alterations (0:00)
ALK (9:49)
ROS1 (22:22)
HER2 (31:00)
RET (38:52)
NTRK (45:30)
MET (46:31)
Novel Targeted Strategies (49:09)
BRAF (54:19)
KRAS G12C (55:38)

CME information and select publications

Non-Small Cell Lung Cancer | Joel W Neal, MD, PhD Jun 08, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD

CME information and select publications

Non-Small Cell Lung Cancer | Jessica J Lin, MD Jun 08, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting ALK, ROS1, RET, TRK and NRG1 — Jessica J Lin, MD

CME information and select publications

For Oncology Nurses: Endometrial Cancer — Proceedings from the 2025 Annual ONS Congress Jun 07, 2025

Show notes

Featuring perspectives from Ms Kathryn M Lyle, Dr Ritu Salani, Ms Jaclyn Shaver and Dr Brian M Slomovitz, including the following topics:

Introduction: Overview of Endometrial Cancer (0:00)
First-Line Therapy for Advanced or Recurrent Endometrial Cancer (11:01)
Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced Endometrial Cancer (39:09)
Novel Investigational Strategies for Newly Diagnosed Advanced Endometrial Cancer (1:00:15)
Incidence and Management of HER2-Positive Endometrial Cancer (1:17:52)

NCPD information and select publications

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances Jun 06, 2025

Show notes

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics:

Introduction: Bispecific Antibodies in Community Practice (0:00)
Diffuse Large B-Cell Lymphoma (7:06)
CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15)
Mantle Cell Lymphoma (32:36)
Follicular Lymphoma (48:08)
CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17)

CME information and select publications

Non-Hodgkin Lymphoma | Stephen M Ansell, MD, PhD Jun 05, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 2: Other Available and Emerging Novel Therapies for NHL — Stephen M Ansell, MD, PhD

CME information and select publications

Non-Hodgkin Lymphoma | Brian T Hill, MD, PhD Jun 05, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 1: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies in Various Non-Hodgkin Lymphoma (NHL) Subtypes — Brian T Hill, MD, PhD

CME information and select publications

Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances Jun 04, 2025

Show notes

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics:

Introduction: Adjuvant CDK4/6 Inhibition (0:00)
HER2-Positive Disease (11:13)
PARP Inhibition (27:34)
Antibody-Drug Conjugates (34:12)
Up-Front Treatment of HR-Positive Metastatic Disease (46:28)

CME information and select publications

Prostate Cancer and AKT Inhibitors — Proceedings from a Session Held During the American Urological Association Annual Meeting Jun 03, 2025

Show notes

Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics:

Introduction (0:00)
Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42)
Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37)
Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18)

CME information and select publications

Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit Jun 02, 2025

Show notes

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: